Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900704 · ClinicalTrials.gov registry record · Phase 3
Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4
A Phase 3 study, sponsored by Serenity Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 810
- Enrollment target
NCT01900704 is a Phase 3 study that has completed, run by Serenity Pharmaceuticals. The registered enrollment target is 810 participants.
The verdict
NCT01900704, a Phase 3 study, has completed, sponsored by Serenity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 810 participants
- Enrollment target
Study Summary
To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia
Interventions
- DRUG Placebo
- DRUG SER120 750 ng
- DRUG SER120 1500 ng
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 810 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01900704
The ClinicalTrials.gov registry entry for NCT01900704 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 810 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Serenity Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01900704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01900704 about?
NCT01900704 is a clinical study titled "Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4". To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia
What is the current status of trial NCT01900704?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 810 participants. The study started on 2013-08. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01900704?
The interventions under investigation include: Placebo (DRUG), SER120 750 ng (DRUG), SER120 1500 ng (DRUG).
Who is sponsoring clinical trial NCT01900704?
This trial is sponsored by Serenity Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.